A research team at Sichuan University in Chengdu have delivered modified cells to a patient with severe lung cancer via the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – Cas9 technique as part of a clinical trial. The researchers say that they are hopeful that their findings will lead to new treatments for patients suffering from this disease. However, Naiyer Rizvi of Columbia University Medical Center in New York City doubts the trial will succeed.
A research team at Sichuan University in Chengdu have delivered modified cells to a patient with severe lung cancer via the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – Cas9 technique as part of a clinical trial. The research team have claimed the first dosage went “smoothly”, but further details were not publicised. However, Naiyer Rizvi of Columbia University Medical Center in New York City doubts the trial will succeed.